Aug 15 (Reuters) - Australia's CSL Ltd (CSL) on Tuesday posted an 8% rise in its annual profit, as strong growth in plasma collections with COVID-19 receding helped the biotech company counter the impact from currency fluctuations and higher costs.
The company posted a net profit after tax of $2.44 billion for the year ended June 30 on a constant currency basis, compared with $2.24 billion in fiscal 2022.
News: CSL Australia's CSL full-year profit rises as plasma collections soar
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$198.37 |
Change
0.030(0.02%) |
Mkt cap ! $96.23B | |||
| Open | High | Low | Value | Volume |
| $200.98 | $203.69 | $198.37 | $647.4M | 3.086M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 428 | $198.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $198.40 | 360 | 2 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| CSL (ASX) Chart |